Lyell Immunopharma : Reports Second Quarter 2021 Financial Results and Business Highlights (Form 8-K) marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Erin Whitney as head of global clinical operations and
Keith White as head of global market access and has also appointed brand strategy consultant
Shauna Horvath to head of global marketing. Whitney joins the team from bluebird bio, while Merck and Genentech veteran White was most recently VP, global market access and pricing at Corbus Pharmaceuticals. Horvath joined Amylyx as a consultant in 2019.
> Culver City, California’s ImmunityBio tapped
Fabio M. Benedetti, M.D., as chief strategy officer, effective Jan. 4. Should ImmunityBio’s NantKwest merger close, Benedetti is expected to assume the role of CSO at the combined company, ImmunityBio said. Benedetti joins from combination therapy specialist Apollomics, where he was chief medical officer.
Looking For The Best Biotech Stocks To Watch Ahead of 2021? 1 Up 300%+ Since March marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
UPDATE - Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to .
Sumitovant BiopharmaDecember 28, 2020 GMT
Myrtle Potter, CEO Sumitovant Biopharma “By forming a transformative collaboration with Myovant Sciences and Pfizer, we have taken steps to help position ORGOVYX for advanced prostate cancer and relugolix once-daily combination for Women’s Health for success.”
Myrtle Potter, CEO Sumitovant Biopharma “By forming a transformative collaboration with Myovant Sciences and Pfizer, we have taken steps to help position ORGOVYX for advanced prostate cancer and relugolix once-daily combination for Women’s Health for success.”
Hits: 1077
Myovant and Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada
Myovant to receive an upfront payment of $650 million in addition to potential regulatory and sales milestones for a total payment of up to $4.2 billion
BASEL, Switzerland and NEW YORK, NY, USA I December 28, 2020 I Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced a collaboration to develop and commercialize relugolix – a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist – in oncology and women’s health in the U.S. and Canada. Pfizer will also receive an exclusive option to commercialize relugolix in oncology outside the U.S. and Canada, excluding certain Asian countries.